Examination of Relationship Between Bilirubin with cytokines and Scores Used as a Marker of Mortality in Patients with Sepsis

The Association of Bilirubin with IL-6, IL-10 and Mortality Scores of Patients with Sepsis

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12612000504819

Enrollment

Registered

2012-05-10

Start date

2010-08-01

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Purpose: Bilirubin has been shown to influence the mechanisms of both apoptosis and inflammation. We investigated the association of bilirubin with sepsis progression. Materials and Methods: Twenty patients from Intensive Care Unit (ICU) were recruited for this study. Patients were divided into two groups: patients diagnosed with sepsis according to the ACCP/SCCM consensus conference criteria (n=10) and patients treated for various other diagnoses (n=10). Blood samples were collected for both groups at the time of origin (defined as the time of diagnosis), and 24 and 48 hours after diagnosis. Serum IL-6, IL-10 and bilirubin levels were analyzed and compared. APACHE II and SOFA scores of the patients were also recorded. Results: At all time intervals, serum IL-6, IL-10, and total, direct, and indirect bilirubin were significantly higher in the sepsis group (p<0.05); APACHE II and SOFA scores were also significantly higher. Both SOFA scores and serum IL-10 levels were positively correlated with bilirubin levels 24 hours after diagnosis (p<0.05, r=-0.76). Conclusion: Although levels of bilirubin and other associated parameters were higher for the sepsis group, only SOFA score and bilirubin levels were correlated. Because bilirubin is already a SOFA parameter, this correlation was not considered clinically significant.

Interventions

1)The patients were classified into two groups: one group, patients diagnosed with sepsis according to the American College of Chest Physicians/Society of Clinical Care Medicine (ACCP/SCCM) consensus conference criteria, other group, patients being treated with a non-sepsis disease in ICU. 2)Blood samples were taken at three time intervals: the time of origin (defined as the day of sepsis diagnosis), 24 hours after diagnosis, and 48 hours after diagnosis. 3)APACHE II (Acute Physiology and Chronic Health Evaluation) and SOFA (Sepsis Related Organ Failure Score) scores were recorded at three time intervals: the time of origin (defined as the day of sepsis diagnosis), 24 hours after diagnosis, and 48 hours after diagnosis.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

20 ICU patients diagnosed with sepsis (according to the American College of Chest Physicians/Society of Clinical Care Medicine (ACCP/SCCM) consensus conference criteria) or other diseases the ages of 18 and 75 receiving mechanical ventilation (SIMV, VT: 6-8 ml/kg, f: 12-14, I/E: 1/2).

Exclusion criteria

Patients with a history of hepatobiliary diseases, jaundice, HBV/HCV sero positivity, renal failure, drug overdose, hemolytic anemia, hypoxia, severe hemodynamic instability, and/or possible brain death were excluded.

Outcome results